Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Trilaciclib|DRUG: Sacituzumab Govitecan-hziy
Sponsor: G1 Therapeutics, Inc.